Kering Expects Sharp Drop in Operating Profit After Gucci Sales Tumble in China — Update
By Andrea Figueras
Kering expects sharply lower operating profit in the first half after sales slumped in the first three months and the company grapples with sluggish demand, particularly in China.
The French luxury-goods giant booked revenue of 4.504 billion euros ($4.80 billion) for the first quarter, down 11% in reported terms compared with the year-earlier period. The result came in line with analysts' forecasts of EUR4.51 billion, according to a poll of estimates compiled by Visible Alpha.
On a comparable basis, revenue fell by 10%, against a backdrop of normalization in the luxury sector and reflecting the turnaround strategy within the group's divisions, it said.
"Kering's performance worsened considerably in the first quarter," Chairman and Chief Executive Francois-Henri Pinault said.
Sales at star brand Gucci--the largest contributor to the group's revenue--dropped 21% in reported terms to EUR2.08 billion, in line with Visible Alpha consensus. On a comparable basis, Gucci revenue fell 18%, hit particularly by a sharp decline in the Asia-Pacific region.
However, the company pointed out that the brand's new collections, which have gradually become available in stores since mid-February, have been very well received, particularly in the ready-to-wear and shoes categories.
"While we had anticipated a challenging start to the year, sluggish market conditions, notably in China, and the strategic repositioning of certain of our houses, starting with Gucci, exacerbated downward pressures on our topline," the CEO said.
Last month, the company warned that first-quarter sales were expected to decline due to a steep sales drop at Gucci in the Asia-Pacific region.
Kering had anticipated a fall of around 10% in group revenue compared with last year's first quarter, while Gucci revenue was expected to tumble by nearly 20% on year.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
April 23, 2024 12:36 ET (16:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing